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The severe acute respiratory syndrome (SARS) epidemic was characterized by high mortality rates in the
elderly. The molecular mechanisms that govern enhanced susceptibility of elderly populations are not known,
and robust animal models are needed that recapitulate the increased pathogenic phenotype noted with
increasing age. Using synthetic biology and reverse genetics, we describe the construction of a panel of isogenic
SARS coronavirus (SARS-CoV) strains bearing variant spike glycoproteins that are representative of zoonotic
strains found in palm civets and raccoon dogs, as well as isolates spanning the early, middle, and late phases
of the SARS-CoV epidemic. The recombinant viruses replicated efficiently in cell culture and demonstrated
variable sensitivities to neutralization with antibodies. The human but not the zoonotic variants replicated
efficiently in human airway epithelial cultures, supporting earlier hypotheses that zoonotic isolates are less
pathogenic in humans but can evolve into highly pathogenic strains. All viruses replicated efficiently, but none
produced clinical disease or death in young animals. In contrast, severe clinical disease, diffuse alveolar
damage, hyaline membrane formation, alveolitis, and death were noted in 12-month-old mice inoculated with
the palm civet HC/SZ/61/03 strain or early-human-phase GZ02 variants but not with related middle- and
late-phase epidemic or raccoon dog strains. This panel of SARS-CoV recombinants bearing zoonotic and
human epidemic spike glycoproteins will provide heterologous challenge models for testing vaccine efficacy
against zoonotic reintroductions as well as provide the appropriate model system for elucidating the complex
virus-host interactions that contribute to more-severe and fatal SARS-CoV disease and acute respiratory
distress in the elderly.
A novel coronavirus (CoV) (11, 26, 27), infecting over 8,422
people during the epidemic of 2002 and 2003, caused severe
acute respiratory syndrome (SARS) illness with a 11% fatality
rate (5). Old age (over 60 years) was found to be significantly
associated with SARS-related deaths (5, 33). Death from
SARS-CoV infection is most often due to rapidly progressive
respiratory compromise (acute respiratory distress syndrome
[ARDS]) and subsequent failure of multiple organs (50), and
age is the only factor associated with the development of
ARDS (4).
The epidemic has been divided into zoonotic, early, middle,
and late phases based on molecular epidemiological studies
(7). The early phase is characterized by a series of independent
cases, possibly of zoonotic origin. The middle phase is charac-
terized by extensive local transmission of the virus, whereas
global transmission to over 30 countries was seen in the late
phase of the epidemic. Unfortunately, few if any zoonotic
strains of SARS-CoV have been successfully isolated and
maintained in culture, preventing their use in vaccine and
pathogenesis studies.
Phylogenetic analysis, coupled with serological and epidemi-
ological studies, has implicated Himalayan palm civets as a
probable source for zoonotic transmission of SARS-CoV to
humans (13, 23). However, recent studies showing a limited
distribution of SARS-CoV in wild animals as well as the ob-
servation that palm civets show relevant clinical signs after
experimental infection with SARS-CoV (61) make these ani-
mals an unlikely reservoir. Currently Chinese horseshoe bats
are believed to be the most likely reservoir of SARS-CoV, with
palm civets and raccoon dogs acting as intermediate hosts (31).
Comparative analyses of the SARS-CoV genomes of differ-
ent isolates from both humans and animals throughout the
different phases of the epidemic showed a high rate of evolu-
tion in the viral attachment protein, the spike (S) glycoprotein
that was critical for the transition from animal-to-human to
human-to-human transmission (7, 23, 42, 53). The S glycopro-
tein binds to the receptor angiotensin-converting enzyme 2
(ACE-2), mediating viral entry and establishing host range (30,
32). A receptor binding domain (RBD) has been defined. Not
surprisingly, the S protein has also been identified as a major
component of protective immunity (17, 56). Several vaccine
* Corresponding author. Mailing address: Department of Epidemi-
ology, 2107 McGavran-Greenberg, CB#7435, University of North
Carolina, Chapel Hill, NC 27699-7435. Phone: (919) 966-3895. Fax:
(919) 966-0584. E-mail: rbaric@email.unc.edu.
 Published ahead of print on 16 May 2007.
7410
 o
n
 June 3, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
candidates based on the S glycoprotein have been successfully
tested in different animal models, showing complete protection
against homologous SARS-CoV challenge (3, 54). In addition,
passive transfer of antibodies directed against the S glycopro-
tein was successful in protecting mice and hamsters against
subsequent challenge with homologous SARS-CoV (46, 55).
Unfortunately, most vaccine candidates have been developed
using nearly identical isolates from the late phase in the epi-
demic, and it is not clear whether these isolates will provide
robust cross protection against zoonotic forms likely to emerge
in the future, especially in vulnerable elderly populations (1,
10). In fact, studies using pseudotyped viruses bearing the S
glycoprotein from different human and animal isolates dem-
onstrated mixed results ranging from no cross-neutralization
with human monoclonal antibodies (MAbs) and even en-
hanced infection to robust cross-neutralization (10, 16, 63).
Given the variable responses of pseudotyped viruses, the goal
of this study was to develop an isogenic panel of recombinant
SARS-CoV isolates bearing variant epidemic and zoonotic S
glycoproteins and evaluate the role of S glycoprotein hetero-
geneity in host tropism and pathogenesis. Developing robust
animal models that recapitulate the complex age-related
pathogenic phenotype, including ARDS, noted during the
SARS-CoV epidemic in humans, is essential for deciphering
the SARS-CoV pathogenic mechanisms. Recombinant viruses
were derived using synthetic biology and reverse genetics to
reconstruct a comprehensive panel of representative SARS-
CoV viruses bearing variant S glycoproteins identified during
the different phases of the epidemic.
MATERIALS AND METHODS
Viruses and cells. The infectious clone (ic) recombinant SARS-CoV Urbani
strain (icUrbani; GenBank accession no. AY27841) and all recombinant viruses
produced in this study were propagated on Vero E6 cells in Eagle’s minimal
essential medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf
serum (HyClone, Logan, UT), kanamycin (0.25 g/ml), and gentamicin (0.05
g/ml) at 37°C in a humidified CO2 incubator.
Growth curve analyses were performed using Vero E6 cultures inoculated with
the different recombinant viruses at a multiplicity of infection (MOI) of 2 for 1 h and
overlaid with medium. Virus samples were collected at various time points postin-
fection and stored at 70°C until viral titers were determined by plaque assay.
Virus titers were determined as PFU by plating six-well plates with 5  105
Vero E6 cells per well and inoculating cultures with 200 l from 10-fold serial
dilutions. Cells were incubated with virus for 1 h at 37°C and overlaid with 3 ml
of 0.8% agarose in media. Plates were incubated for 2 days at 37°C, and plaques
were visualized by staining with neutral red for 3 h and counted. Virus concen-
trations were calculated as PFU/ml.
All work was performed in a biological safety cabinet in a biosafety level 3
laboratory containing redundant exhaust fans. Personnel were equipped with
powered air-purifying respirators with high-efficiency particulate air and organic
vapor filters (3M, St. Paul, MN), wore Tyvek suits (DuPont, Research Triangle
Park, NC), and were double gloved.
Bioinformatic analysis of the SARS-CoV spike gene. The S gene of viral
sequences representing early, middle, and late phases of the SARS-CoV epi-
demic in humans and zoonotic strains of SARS-CoV isolated from palm civets
and raccoon dogs found in Chinese live-animal markets or housed on farms in
China were aligned using ClustalX 1.83 with default settings (6). Molecular
phylogenetic reconstruction was conducted using Bayesian inference as imple-
mented in the program MrBayes v3.0b4 (21). Briefly, the alignment was exported
in the nexus format, the amino acid substitution model was set to JTT (22) with
the lset command, and Markov chain Monte Carlo simulation (15, 21) was used
to approximate the posterior probabilities of trees, with sampling conducted on
four chains over 500,000 generations (48). Trees were sampled every 100 gen-
erations, and the 5,001 trees collected were summarized with the sumt command
set to a burnin of 1,000, which generated a consensus tree using the 50% majority
rule (48). The burnin value was determined using the sump command with an
arbitrary burnin of 250, which demonstrated that stationarity occurred prior to
the 100,000th generation, indicating that a burnin of 1,000 was appropriate for
the sumt command (48).
Five representative sequences were selected as representatives of important
clusters, including the Urbani strain (GenBank accession no. AY27841), repre-
senting the late phase of the human epidemic, CUHK-W1 (GenBank accession
no. AY278554), representing the middle phase, GZ02 (GenBank accession no.
AY390556), representing the early phase, HC/SZ/61/03 (GenBank accession no.
AY515512), representing zoonotic SARS-CoV isolated from a Himalayan palm
civet, and A031G (GenBank accession no. AY687358), representing zoonotic
SARS-CoV isolated from a raccoon dog.
Construction of recombinant viruses. Spike glycoprotein sequences for strains
CUHK-W1 (GenBank accession no. AY278554), GZ02 (GenBank accession no.
AY390556), HC/SZ/61/03 (GenBank accession no. AY515512), and A031G
(GenBank accession no. AY687358) were used to replace the S glycoprotein of
the Urbani strain (GenBank accession no. AY27841) in the E and F fragments
of the icUrbani. For the CUHK-W1 and GZ02 strains, S glycoprotein synthetic
DNA (Blue Heron Biotechnology, Bothell, WA), a BglI, starting at an NcoI
restriction site at nucleotide position 21920 and ending at nucleotide position
24067, was purchased. The NcoI/BglI fragment was excised, purified, and ligated
into the icUrbani-CoV E fragment, replacing the Urbani S glycoprotein se-
quence, and subclones were sequenced. For CUHK-W1 no additional nucleotide
changes were needed in the C terminus of the S glycoprotein, which is coded in
the F fragment of icUrbani. For GZ02, the F fragment of GD03T0013 (GenBank
accession no. AY304486), a cDNA previously constructed in our laboratory (10),
was used, as the sequences are identical in this domain.
For strain HC/SZ/61/03, a synthetic DNA was purchased that encodes nucle-
otide positions 21542 to 24067 containing the appropriate mutations and is
flanked by AgeI and BglI restriction sites. The synthetic DNA was subcloned into
the E fragment of icUrbani, and appropriate subclones were identified by se-
quence. An additional mutation in the F fragment was generated by overlap PCR
mutagenesis. Amplicon A was generated using primer set BR29 (5-GTGTTTA
GTGGCACTTCTTG-3) and HC-673rv (5-GAATAACCACCAATTTGGTA-
3), amplicon B was generated using HC-673fw (5-CACAAGCAGCCCCGC-
3) and BR30 (5-CAAGAAGTGCCACTAAACAC-3), and the overlap PCR
was performed with primer sets BR29 and BR30. The product was subcloned
into the F fragment of GD03T0013 by use of flanking BbsI restriction sites, and
the sequence was verified.
To generate an A031G S gene, two additional mutations in the E fragment of
HC/SZ/61/03 were generated by overlap PCR mutagenesis. Amplicon C was
generated using primer set BR24 (5-GCTGCAGCCTATTTTGTTG-3) and
BR25 (5-GCCATCAGAAGAGAAAGG-3), amplicon D was generated using
BR26 (5-CCTTTCTCTTCTGATGGC-3) and BR27 (5-CTAGGCATTGGC
CATATTG-3), and amplicon E was generated using BR28 (5-CAATATGGC
CAATGCCTAG-3) and Erv (5-GAGCAGCCGTGTAGGCAGCAAT-3). An
overlapping product of amplicons C, D, and E was generated by use of primer set
BR24 and Erv, the product was subsequently subcloned into the E fragment of
HC/SZ/61/03 by use of flanking PstI and BglI restriction sites, and the sequence
was verified. For A031G, no additional changes were needed in the F fragment
of HC/SZ/61/03, as the sequences are identical in this domain.
Full-length cDNAs were constructed and transfection of full-length transcripts
was performed as previously described (65). The transfected Vero E6 cells were
seeded in a 75-cm2 flask and monitored for cytopathic effect (CPE). If the
resulting icSARS-CoV isolate did not induce CPE at passage 0, cells were passed
in Vero E6 cells until a strong CPE phenotype emerged. Viruses were plaque
purified and intracellular RNA was isolated from infected cultures by use of
TRIzol reagents as directed by the manufacturer (Invitrogen, Carlsbad, CA).
The S gene was amplified by reverse transcription-PCR into two products by use
of primer sets Leader (5-AAAGCCAACCAACCTCGATC-3) and S2rv (5-G
GTCTCAAGCAATTGAACTATCAGC-3) to produce amplicon Spike-1, while
SR2fw (5-GGTCTCTTGCTTACTCTAATAACACC-3) and SRv (5-GGTCT
CCGTTTATGTGTAATGTAATTT-3) were used to amplify the Spike-2 prod-
ucts. Products were cloned into a pCR-XL-TOPO vector (Invitrogen, Carlsbad,
CA) and sequenced. Stocks of viruses were grown in 150-cm2 flasks and stored
at 70°C until further use.
ACE2 blocking assay. Vero E6 cultures were seeded at 5  105 cells/well in
six-well plates. The cells were incubated with twofold dilutions of an anti-human
ACE-1 or ACE-2 ectodomain antibody (AF929 or AF933; R&D Systems, Min-
neapolis, MN) starting at 10 g/well for 1 h at 37°C. A control well without
antibody was included on each plate. Cells were subsequently inoculated with 50
PFU of icUrbani, icCUHK-W1, icGZ02, icHC/SZ/61/03, or icA031G in the
presence of antibodies. After a 1 h incubation period at 37°C, unbound virus and
antibody was removed by washing the cells three times with phosphate-buffered
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saline (PBS). After the last wash, cells were overlaid with 3 ml of 0.8% agarose
in media. Plates were incubated for 2 days at 37°C and stained with neutral red
for 3 h, and plaques were counted. The percentage of blocking was calculated as
follows: 1  (number of plaques with antibody/number of plaques without
antibody)  100%.
Cathepsin inhibition assay. Vero E6 cells were cultured at 5  105 cells/well
in six-well plates. The cells were incubated with twofold dilutions of cathepsin K
inhibitor II, cathepsin L inhibitor III, or cathepsin S inhibitor (Calbiochem, San
Diego, CA) starting at 104 M/well for 1 h at 37°C. A control well without a
cathepsin inhibitor was included on each plate. Cells were subsequently inocu-
lated with 50 PFU of icUrbani, icCUHK-W1, icGZ02, icHC/SZ/61/03, or
icA031G in the presence of the respective cathepsin inhibitor. After a 1 h
incubation period at 37°C, cells were overlaid with 3 ml of 0.8% agarose in media
containing the respective cathepsin inhibitors. Plates were incubated for 2 days at
37°C and stained with neutral red for 3 h, and plaques were counted. The
percentage of blocking was calculated as follows: 1  (number of plaques with
cathepsin inhibitor/number of plaques without cathepsin inhibitor)  100%.
HAE cell cultures. Human ciliated airway epithelial (HAE) cell cultures were
prepared and maintained as described previously (52). Briefly, freshly isolated
tracheobronchial primary cells were expanded on plastic to generate passage 1
cells and then plated onto semipermeable Transwell-Col (12-mm-diameter) sup-
ports. HAE cell cultures were generated by provision of an air-liquid interface
for 4 to 6 weeks to form well-differentiated polarized cultures that recapitulate
the human pseudostratified ciliated airway epithelium.
HAE cell cultures from two different patients were inoculated via the apical
surface with 106 PFU in 200 l of each recombinant virus at a high (2) MOI in
duplicate. Prior to inoculation, the apical surfaces of HAE cell cultures were
rinsed three times over 30 min with PBS at 37°C to remove accumulated secre-
tions. Following a 2-h inoculation at 37°C, all inocula were removed and HAE
cell cultures were maintained at an air-liquid interface for the remainder of the
experiment. Samples for growth curve analysis were taken by incubating 500 l
of medium for 10 min at 37°C, collecting the medium, and storing at 70°C
before plaque titration.
Histological sections of paraffin-embedded HAE cell cultures were prepared
as previously described (52). Briefly, sections were incubated with mouse mono-
clonal antibodies raised against SARS nucleoprotein (immunoglobulin gG2a
[IgG2a]) and acetylated alpha-tubulin (IgG2b). Immunoreactivity was visualized
by use of secondary antibodies against mouse IgG2a conjugated to fluorescein
and mouse IgG2b conjugated to rhodamine. Images were taken on a Leica
fluorescence microscope using a tricolor filter as previously described (52).
Virus neutralization assay. Three MAbs against Urbani (341CD, 283CD, and
540CD; kindly provided by L. J. Anderson, CDC, Atlanta, GA) and seven human
convalescent-phase serum samples from patients infected with a late-phase iso-
late of SARS-CoV (kindly provided by D. Kelvin, Toronto General Research
Institute, Toronto, Ontario, Canada) were used in a neutralization assay. Sam-
ples were collected at discharge from hospital from convalescent Toronto-area
SARS patients enrolled without bias to age, sex, or previous medical history.
SARS patients had been confirmed for SARS-CoV infection by positive PCR
and/or seroconversion results. The cohort was comprised of three males and four
females, with a median age of 39 years. Informed consent was obtained from all
subjects with the approval of the Research Ethics Boards of the University
Health Network and participating Toronto-area hospitals. Monoclonal antibod-
ies or convalescent-phase serum samples were serially diluted twofold, starting at
500 g/ml for the mouse MAbs, and incubated with 100 PFU of strain icUrbani,
icCUHK-W1, icGZ02, icHC/SZ/61/03, or icA031G for 1 h at 37°C. Virus and
antibodies were then added to a 96-well plate with 5  103 Vero E6/well at 10
wells per antibody dilution. Wells were checked for CPE at 4 to 5 days postin-
fection. A 50% neutralization titer was determined as the antibody dilution at
which 5 wells showed no CPE.
Mouse infection. Female BALB/c mice (6-week-old BALB/cAnNCrl mice
from Charles River Laboratories and 12-month-old BALB/cBy mice from the
National Institute on Aging) were anesthetized with a ketamine (1.3 mg/mouse)-
xylazine (0.38 mg/mouse) mixture administered intraperitoneally with a 50-l
volume. Each mouse was intranasally inoculated with 105 PFU (strains icUrbani,
icCUHK-W1, icGZ02, and icA031G) or 2  104 PFU (strain icHC/SZ/61/03) of
virus in a 50-l volume (highest dose possible for icHC/SZ/61/03). At 2 and 4
days postinfection, lung, spleen, liver, kidney, and brain serum and tissue samples
were removed and frozen at 70°C for later plaque assay determination of viral
titers. Lung, spleen, liver, kidney, and intestinal tissues were removed for histo-
logical examination.
All mice were housed under sterile conditions using individually ventilated
Sealsafe cages and the SlimLine system (Tecniplast, Exton, PA). Experimental
protocols were reviewed and approved by the Institutional Animal Care and Use
Committee at University of North Carolina, Chapel Hill.
Virus titers in tissue samples. Tissue samples were weighed and homogenized
in five equivalent volumes of PBS to generate a 20% solution. The solution was
centrifuged at 13,000 rpm under conditions of aerosol containment in a table-top
centrifuge for 5 min, the clarified supernatant serially diluted in PBS, and 200-l
volumes of the dilutions placed onto monolayers of Vero E6 cells in six-well plates.
Following a 1-h incubation at 37°C, cells were overlaid with 0.8% agarose-containing
medium. Two days later, plates were stained with neutral red and plaques counted.
Histology. All tissues were fixed in 4% paraformaldehyde in PBS (pH 7.4)
prior to being submitted to the Histopathology Core Facility (University of North
Carolina, Chapel Hill) for paraffin embedding, sectioning at 5-m thickness, and
hematoxylin and eosin staining. Approximately one-quarter of the total lungs
were sectioned, with three sections mounted from cuts taken at three different
depths within the paraffin-embedded tissue. The same sets of tissues were also
evaluated qualitatively by a veterinary respiratory pathologist.
RESULTS
Selection of representative Spike variants of SARS-CoV.
The outbreak of SARS-CoV of 2002 and 2003 had previously
been divided into zoonotic, early, middle, and late phases
based on molecular epidemiological studies (7). For this study
all the complete genomes available from both human and
animal isolates of SARS-CoV (54 sequences) in spring 2005
were analyzed, and 27 representative sequences were used to
create a phylogenic tree showing the different phases of the
epidemic (Fig. 1A). Bayesian analysis was used to identify
strains clustering among zoonotic pools or the early, middle, or
late phase of the epidemic. S glycoprotein core sequences were
determined by removing single nucleotide polymorphisms
unique to individual strains followed by clustering to identify
core S sequences representative of each group. Individual
strains were chosen that retained this core sequence of late
(strain Urbani)-, middle (CUHK-W1)-, and early (GZ02)-
phase epidemic isolates or were designed to represent unique
zoonotic strains such as HC/SZ/61/03 from palm civets and
A031G from raccoon dogs, as these strains were identified as
encoding the most divergent Spike gene in animal markets
(23). The isolates had a minimum similarity of 99% throughout
the SARS-CoV genome. By aligning the S genes of these
different isolates, 23 amino acid changes were identified (Fig.
1B). Eight of these amino acid changes were localized within
the RBD, one in the putative fusion peptide (FP) domain, and
one in the heptad repeat 2 (HR-2) domain.
Reconstruction of Spike variants of SARS-CoV. Synthetic
gene segments coupled with site-specific mutagenesis were
used to produce SARS-CoV E and F subclones containing the
heterologous S genes. Full-length cDNAs were assembled and
transcripts electroporated into Vero E6 cells. Introduction of
the S gene changes into the S gene of strain icUrbani produced
replicating virus, as determined by detection of leader-contain-
ing transcripts (data not shown). However, only icUrbani,
icCUHK-W1, and icGZ02 produced CPE (rounding and cell
death) within 48 h after transfection. In contrast, the zoonotic
isolates icHZ/SZ/61/03 and icA031G did not produce a notable
CPE after transfection, and infected cells were subsequently
passed every 48 h until CPE was detected. Importantly, CPE
was observed for icHC/SZ/61/03 and icA031G at passages 5
and 6, respectively. All viruses were plaque purified and stocks
amplified in Vero E6 cells.
Cell culture adaptation of variant SARS-CoV. To determine
whether tissue culture passage had selected for second-site
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mutations that enhanced the cytopathology of the zoonotic
strains in vitro, the S genes from all rescued, plaque-purified
recombinant viruses were cloned and sequenced. Sequence
analysis revealed no codon changes within the S glycoprotein
of isolates icUrbani, icCUHK-W1, and icGZ02. In contrast, a
single amino acid change was identified at position 578 and at
position 577 in icHC/SZ/61/03 and icA031G, respectively. To
identify possible cell culture-adapting mutations in the other
structural and accessory open reading frames (ORFs) the re-
maining 3 ends of the icSARS-CoV isolates were sequenced,
revealing no additional amino acid changes throughout the 3
end of each recombinant virus genome (8.5 kb).
Effect of Spike mutations on in vitro replication. The repli-
cation efficiency of recombinant viruses bearing heterologous S
glycoproteins was evaluated in Vero E6 cells. Cultures were
infected at an MOI of 2 and growth kinetics determined over
the next 32 h. All viruses replicated efficiently in Vero E6 cells,
achieving peak titers after 24 to 32 h postinfection (Fig. 2A).
Growth kinetics of recombinant viruses bearing zoonotic S
glycoproteins were delayed in comparison to those of the pa-
rental icUrbani control. The virus bearing the palm civet S
glycoprotein (HC/SZ/61/03) achieved peak titers at 32 h posti-
noculation (p.i.) of only around 105 PFU/ml, a reduction of 1
log (t test; P  0.05). Although they were delayed, the raccoon
dog icA031G isolate displayed growth kinetics similar to those
of epidemic strains whereas the icHC/SZ/61/03 isolate repli-
cated less efficiently.
To assess virus growth in a culture system more relevant to
FIG. 1. (A) Phylogenetic analysis of SARS-CoV variants isolated during the zoonotic and human phases of the epidemic. An unrooted phylogenetic
gene tree of the complete genomes of 27 SARS-CoV isolates ranging from those collected from humans in early, middle, and late phases of the epidemic
of 2002 of 2003 to zoonotic isolates collected in 2003 and 2004 is presented. Isolates selected as representative of spike glycoprotein sequences of zoonotic
(HC/SZ/61/03 and A031G) and early (GZ02)-, middle (CUHK-W1)-, and late (Urbani)-phase human isolates are shown in shaded boxes. The black bar
represents percent divergence. (B) Amino acid changes in the SARS-CoV spike glycoprotein of zoonotic and human epidemic isolates. A.A., amino acid;
A031G, raccoon dog; HC/SZ/61/03, palm civet; GZ02, early human phase; CUHK-W1, middle human phase; Urbani, late human phase.
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humans, and since it has been previously shown that SARS-
CoV infects human ciliated airway epithelial cells, we used
human ciliated airway epithelial cultures to determine virus
growth kinetics (52). All SARS-CoV strains bearing S glyco-
protein variants from human isolates (icUrbani, icCUHK-W1,
and icGZ02) spanning the early, middle, and late phases of the
epidemic efficiently replicated in HAE cell cultures, with cili-
ated epithelial cells being the primary targets of infection (data
not shown). Growth curves for the early-phase icGZ02 isolate
were similar to late-phase or wild-type icUrbani results, where-
as the growth kinetics of the middle-phase isolate icCUHK-W1
were delayed compared to Urbani isolate results (Fig. 2B).
However, all epidemic human strains replicated with a 2 log
increase in titers by 72 h p.i. (106 PFU/ml for icUrbani and
icGZ02 and 104.5 PFU/ml for CUHK-W1). Importantly, re-
combinant SARS-CoV isolates bearing zoonotic spikes did not
replicate efficiently in HAE cell cultures and virus titers did not
increase during the first 72 h of infection. Similar results were
seen with HAE cell cultures derived from two different pa-
tients; however, peak virus titers differed. As shown by the
results of immunofluorescent staining with antisera directed
against the icSARS N protein, epidemic human strains icUr-
bani, icGZ02, and icCUHK-W1 readily infected ciliated cells
in culture (Fig. 2C). In contrast, ciliated cells were not infected
in icHC/SZ/61/03- and icA031G-infected cultures (Fig. 2D).
Effect of Spike mutations on receptor usage and entry. Pre-
vious studies have suggested that some zoonotic strains may
use alternative receptors for docking and entry into the host
cell (63). In order to determine whether the variant S strains of
SARS-CoV used ACE-2 as a receptor, the receptor was
FIG. 2. In vitro growth characteristics of recombinant SARS-CoV spike glycoprotein variants and their use of ACE-2 and cathepsin L for
binding and entry. (A and B) Cultures of Vero E6 cells (A) or human airway epithelium cells (B) were infected in duplicate with the S glycoprotein
variants at a high MOI of 2 or 1, respectively, as described in Materials and Methods. Virus titers at different time points were determined by
a plaque assay using Vero E6 cells. (C and D) HAE cell cultures infected with the icUrbani (C) or icHC/SZ/61/03 (D) isolate were stained for
icSARS-CoV nucleoprotein (green) and alpha-tubulin (red) with mouse MAbs as described in Materials and Methods, with original magnifications
of 100. Staining of HAE infected with icUrbani was representative of icCUHK-W1 and icGZ02 and of HAE infected with icHC/SZ/61/03 was
representative of icA031G. (E and F) To determine the role of ACE-2 and cathepsin L in binding and entry of the different S variants, Vero E6
cells were pretreated with polyclonal antibodies directed against either human ACE-2 (E) or cathepsin L inhibitor III (F) and infected with
recombinant SARS-CoV spike glycoprotein variants as described in Materials and Methods. Blocking results are expressed as the mean
percentages of plaque numbers in anti-human ACE2- or cathepsin L inhibitor-treated Vero E6 cells relative to untreated cell results.  with solid
black line, icUrbani; E with dashed black line, icCUHK-W1; with dotted black line, icGZ02; with solid gray line, icHC/SZ/61/03; 	 with dotted
gray line, icA031G. Error bars represent standard deviations.
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blocked by human ACE-2-specific polyclonal antibodies prior
to infection with icSARS-CoV bearing the zoonotic and epi-
demic S variants. Infection was completely inhibited by block-
ing ACE-2 on Vero E6 for all variants (Fig. 2E); these data
suggest that zoonotic and epidemic strains all use ACE-2 as a
receptor for entry into Vero E6 cells. No blockade was ob-
served when cells were pretreated with polyclonal antibodies
directed against ACE-1 as a negative control.
Recently, two studies demonstrated the dependence of
SARS-CoV on the presence of cathepsin L for entry and in-
fection of cells (19, 51). In order to determine whether cathep-
sin L was essential for epidemic and zoonotic virus entry into
cells, cultures of Vero E6 cells were pretreated with cathepsin
L inhibitor III prior to infection with the variant S panel.
Infection of Vero E6 cells with SARS-CoV bearing variant
spikes was highly sensitive to pretreatment with cathepsin L
inhibitor (Fig. 2F). No obvious difference in infection results
was observed, although both icGZ02 and icHC/SZ/61/03 were
about a half-log more sensitive to cathepsin L inhibition than
the other viruses. No block in virus entry was observed when
using cathepsin K or S inhibitors as controls, demonstrating the
specificity of the block to entry of the panel of S variants (data
not shown).
Effect of Spike mutations on binding of neutralizing anti-
bodies. Several of the S mutations fall within the RBD as well
as other regions shown to elicit neutralizing antibodies (24, 28,
57). To study the effect of these mutations on the ability of
monoclonal antibodies to neutralize both homologous and het-
erologous viruses, SARS-CoV isolates bearing the spike vari-
ants were incubated with murine monoclonal antibodies pre-
viously shown to neutralize the Urbani isolate (58). For all
three MAbs, the highest neutralizing titers were directed
against the homologous icUrbani isolate (Fig. 3). Similar titers
were observed with the other two human isolates, icCUHK-W1
and icGZ02, and MAb 341CD. However, recombinant viruses
bearing GZ02 S glycoproteins were not neutralized efficiently
by 540CD or 283CD (analysis of variance [ANOVA]; P 
0.01). Not only were neutralization titers against the zoonotic
spike variants significantly reduced but measurable values were
observed only when using 10-fold concentrations of MAb.
When convalescent-phase serum samples from patients in-
fected with a late-phase SARS-CoV isolate were used, the
homologous icUrbani variant was most potently neutralized
(ANOVA; P 0.01) (Fig. 3). Moreover, both the other human
and zoonotic S variants were effectively neutralized using hu-
man convalescent-phase serum samples but were 5-to 10-fold
more resistant that icUrbani.
Effect of Spike mutations on in vivo replication. SARS-CoV
infection of 6-week-old BALB/c mice with the S variants did
not result in the clinical signs of disease previously described
for the Urbani strain (55). As with the parental icUrbani strain
results, all groups of animals continued to gain weight regard-
less of the origin of the S glycoprotein (Fig. 4A). The viruses
replicated efficiently in the respiratory tract and achieved peak
titers of between 106 and 107 PFU/gram of lung tissue on day
2 p.i. (Fig. 4B), with a 1 to 2 log reduction in titers by day 4.
Aged BALB/c mice have been previously shown to develop
mild clinical signs of disease, including limited weight loss and
FIG. 3. Homologous and heterologous neutralization of recombi-
nant SARS-CoV spike glycoprotein variants by mouse monoclonal
antibodies and human convalescent-phase sera. Serial diluted samples
of mouse monoclonal antibodies (341CD, 540CD, and 283CD) and
seven convalescent human serum samples from SARS cases (Human
sera) were tested for the neutralizing ability of 100 PFU of differ-
ent recombinant SARS-CoV spike glycoprotein variants (icUrbani,
icCUHK-W1, icGZ02, icHC/SZ/61/03, and icA031G) as described in
Materials and Methods. Results are expressed as the dilution of anti-
body at which 50% of the viruses are neutralized. Error bars represent
standard deviations.
FIG. 4. Weight loss and lung titer results for 6-week-old female
BALB/c mice infected with recombinant SARS-CoV spike glycopro-
tein variants icUrbani (), icCUHK-W1 (E), icGZ02 (), icHC/SZ/
61/03 (), and icA031G (	) and mock infected (diao). Mice were
intranasally inoculated with 105 PFU of the SARS-CoV S variants in
50 l PBS. (A) Body weights of infected mice were measured on a daily
basis (n
 10 per group until day 2 and 5 per group until day 4). Weight
changes are expressed as the mean percent changes for infected ani-
mals relative to the initial weights at day 0. (B) Lung tissues were
harvested from infected mice on day 2 (black bars) and day 4 (white
bars) postinfection and assayed for infectious virus as described in
Materials and Methods. Tissue samples from five mice were analyzed
at each time point. Error bars represent standard deviations.
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lung pathology, after inoculation with icUrbani strain SARS-
CoV (45). In agreement with that observation, inoculation of
12-month-old BALB/c mice with icUrbani resulted in signs of
clinical illness characterized by weight loss (Fig. 5A), hunching,
and ruffled fur. Significant weight loss began 2 days p.i., peak-
ing at a 12% loss in body weight by day 4 p.i. (ANOVA; P 
0.01). Interestingly, infection with icCUHK-W1, which only
differs from icUrbani in two amino acids in the spike protein,
resulted in only minor weight loss (maximum of 5% on day 3);
no other clinical signs were observed. Surprisingly, infection
with two of the spike variants, icGZ02 and icHC/SZ/61/03,
resulted in a marked decrease in weight (12% on day 3 for
icHC/SZ/61/03 and up to 19% on day 4 for icGZ02), hunching,
ruffled fur, and difficulty breathing on day 3 and 4 p.i. Animals
inoculated with icHC/SZ/61/03 began to die after 3 days, with
all animals succumbing to infection by day 4 (Fig. 5B). In
contrast, three out of five animals infected with icGZ02 died by
day 4.
As noted with respect to the results obtained with younger
animals, icSARS-CoV isolates replicated to high titers in the
lungs (Fig. 5C). Interestingly, one of the lethal recombinant
viruses, icHC/SZ/61/03, grew to titers that were 2 and 3.5 logs
lower than those seen with icGZ02 on day 2 and 4, respectively.
The zoonotic S variants generally grew to lower titers in older
animals compared to the results seen with younger mice (t test;
P 0.05), while the human isolates icUrbani and icGZ02 grew
to higher titers (t test; P  0.05). To determine whether icHC/
SZ/61/03 had different tissue tropism characteristics, virus ti-
ters were determined in serum, liver, kidney, spleen, and brain
tissue samples. Low titers of virus could be found in serum,
liver, spleen, and kidney tissue samples (103, 104, 102, and 101
PFU/gram tissue, respectively) with no significant differences
between the results for the different viruses, and no virus could
be detected in the brain tissue samples (data not shown).
Lung histopathology. Six-week-old mice that were infected
with the strain icUrbani, icCUHK-W1, or icA031G S variants
showed minimal or no bronchiolar or alveolar pathology,
whereas mice infected with icGZ02 or icHC/SZ/61/03 had only
minimal to mild bronchiolitis. Minimal or no alveolitis was
present in the pulmonary parenchyma of these young mice at
either 2 or 4 days p.i. (Fig. 6). The bronchiolar epithelium of
infected young mice had only widely scattered individual cell
degeneration and necrosis at 2 days p.i., with no obvious epi-
thelial loss or attenuation. Some associated peribronchiolar
and perivascular inflammatory cell infiltration (mainly of lym-
phocytes with lesser numbers of neutrophils) was also ob-
served. By 4 days p.i. there was some microscopic evidence of
epithelial regeneration, i.e., mild hypertrophy-hyperplasia and
scattered intraepithelial mitotic figures.
Interestingly, the most severe, viral infection-induced lung
lesions were present in 12-month-old mice that were infected
with strain icGZ02 or icHC/SZ/61/03. At 2 days p.i., these mice
exhibited marked necrotizing bronchiolitis. This lesion was
characterized by degeneration, necrosis, and exfoliation of the
luminal surface epithelium lining preterminal and terminal
bronchioles accompanied by a mixed inflammatory cell infil-
trate of mainly large and small lymphocytes, lesser numbers of
neutrophils, and only occasional eosinophils (Fig. 7). This in-
tramural inflammatory cell response was present in the peri-
bronchiolar interstitium, surface epithelium, and airway lu-
mens. Large, vacuolated airway macrophages, many laden with
phagocytic cellular material, were often present along with
exfoliated, necrotic, cellular debris within the lumens of these
affected small conducting airways.
By 4 days p.i. the necrotizing bronchiolitis in the lungs of
these 12-month-old mice was still present, with marked loss
and/or attenuation of the bronchiolar epithelium (Fig. 6). This
was accompanied by widespread injury of the alveolar paren-
chyma. The histopathology of this injury to the gas exchange
region of the lung consisted of diffuse acute alveolitis, intersti-
tial edema, and congestion in the alveolar septa and around
small blood vessels, scattered microthrombi in septal capillar-
ies, and conspicuous deposition of eosinophilic fibrinous ma-
FIG. 5. Weight loss, mortality, and lung titers of 12-month-old fe-
male BALB/c mice infected with recombinant SARS-CoV spike gly-
coprotein variants icUrbani (), icCUHK-W1 (E), icGZ02 (), icHC/
SZ/61/03 (), and icA031G (	) and mock infected (diao). Mice were
intranasally inoculated with 105 PFU of the SARS-CoV S variants in
50 l PBS. (A and B) Body weights (A) and accumulated mortality
(B) of infected mice were measured on a daily basis (n 
 10 per group
until day 2 and n 
 5 per group until day 4). Weight changes are
expressed as the mean percent changes in infected animal relative to
the initial weights at day 0. (C) Lung tissues were harvested from
infected mice on day 2 (black bars) and day 4 (white bars) postinfec-
tion and assayed for infectious virus as described in Materials and
Methods. Tissue samples from five mice were analyzed at each time
point. Error bars represent standard deviations.
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terial both in the alveolar septal walls and organized as hyaline
aggregates in the alveolar air spaces (hyaline membranes) (Fig.
8). Diffuse alveolar damage (DAD), interstitial edema, and
hyaline membrane formation are characteristic of ARDS.
In contrast to these marked pulmonary lesions in the12-
month-old mice infected with strains icGZ02 and icHC/SZ/61/
03, mice of a similar age infected with icA031G, icCUHK-W1,
or icUrbani had only minimal to mild bronchiolitis character-
ized by a modest peribronchiolar infiltrate of mixed inflamma-
tory cells (mainly lymphocytes, with lesser numbers of neutro-
phils and eosinophils) and only occasional individual cell
degeneration and cell death in the surface epithelium (Fig. 7).
These bronchiolar changes were less severe at 4 days compared
to 2 days p.i. Unlike the 12-month-old mice infected with strain
icGZ02 or icHC/SZ/61/03, these mice had no or minimal acute
alveolitis with no other alveolar lesions (e.g., hyaline mem-
branes or interstitial edema). No pulmonary pathology was
evident in designated control mice that received mock inocu-
lations and were sacrificed at 6 weeks or 12 months of age (Fig.
6, 7, and 8).
DISCUSSION
The emergence of SARS-CoV, Hendra virus, and H5N1
from zoonotic reservoirs oftentimes involves a series of adap-
tive mutations that evolve over time. In most instances, exten-
sive sequence databases of complete and partial viral genomes
have identified the genetic diversity that exists in animal res-
FIG. 6. Light photographs of preterminal bronchioles and terminal bronchioles (PB and TB, respectively) in the lungs of 6-week-old (A, C, and
E) or 12-month-old (B, D, and F) BALB/c mice that were mock inoculated (A and B) or inoculated with recombinant SARS-CoV S glycoprotein
variant isGZ02 (C and D) or icHC/SZ/61/03 (E and F) and sacrificed 4 days postinoculation. Bronchiolitis with marked attenuation or loss (arrows
with closed arrowheads) of the surface epithelium (e) lining the bronchiolar lumen is present in bronchioles of 12-month-old mice infected with
the viral variants (D and F) but not in the much younger, 6-week-old mice that were similarly exposed to these viral strains (C and E).
Virus-induced peribronchiolar inflammation is evident in both young and old mice (dotted arrows with open arrowheads). AL, alveoli; AD,
alveolar ducts; BV, blood vessels. Tissues were stained with hematoxylin and eosin. Scaling bars, 50 m.
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ervoirs, and yet only a limited number of these viruses have
been successfully isolated from cell culture. As these zoonotic
reservoirs likely harbor future epidemic strains, new methods
are needed to reconstitute viruses encoding these functional
gene sets for vaccine and pathogenesis studies. In this study we
used synthetic biology and reverse genetics to construct a set of
isogenic recombinant viruses bearing variant S glycoproteins to
analyze the role of SARS-CoV S glycoprotein heterogeneity in
virus-host interactions and immune evasion.
For use in a model system to develop synthetic genomics as
a means of reconstructing viable viruses from sequence data-
bases, the SARS-CoV outbreak is uniquely defined by a chro-
nological set of sequence changes that span the epidemic
strains, providing an unparalleled opportunity to identify the
genetic basis for zoonotic virus cross-species transmission and
pathogenesis during an expanding epidemic (7). Our phyloge-
netic studies, in agreement with earlier studies using fewer
strains (7), identified a core set of conserved mutations that
evolved and were maintained throughout each phase of the
expanding epidemic. The early phase was initially character-
ized by a series of independent cases likely due to zoonotic
transmission events (reviewed in reference 66). The middle
phase refers to the major outbreak of SARS-CoV in a Guang
Dong hospital, where a superspreader event was associated
with more than 130 primary and secondary infections. The late
phase started at hotel M in Hong Kong, from which virus was
transmitted to Vietnam, Singapore, Canada, and the United
States. Briefly, by comparing the early-, middle-, and late-
FIG. 7. Light photographs of preterminal bronchioles and terminal bronchioles (PB and TB, respectively) in the lungs of 12-month-old BALB/c
mice that were mock inoculated (A) or inoculated with recombinant SARS-CoV spike glycoprotein variant icUrbani (B), icGZ02 (C), icHC/SZ/
61/03 (D), icCUHK-W1 (E), or icA031G (F) and sacrificed 2 days after inoculation. Acute necrotizing bronchiolitis with epithelial cell exfoliation
(solid arrows with closed arrowhead) is most prominent in panels C and D, with lesions of lesser severity in the mice infected with the other S
variants (B, E, and F). No epithelial (e) or inflammatory lesions are present in the bronchiole from the control mouse (A). AL, alveoli; AD, alveolar
ducts; BV, blood vessels; AS, alveolar septa. Dotted arrows with open arrowheads represent peribronchiolar inflammatory cell infiltration. Tissues
were stained with hematoxylin and eosin. Scaling bars, 50 m.
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phase human isolates (GZ02, CUHK-W1, and Urbani, respec-
tively) to the palm civet isolate HZ/SZ/61/03 and the raccoon
dog isolate A031G, 23 amino acid variations were noted in the
S glycoprotein which varied in a coordinated time-sensitive
fashion during the outbreak. Structural analysis has identified
changes at positions L479N and T487S showing that these are
key residues for efficient human ACE2 receptor usage (29, 32);
however, the functional significance of the remaining 21 codon
changes is unknown. In addition to the S glycoprotein muta-
tions, it has been hypothesized that many replicase- and group-
specific ORF mutations were also key to an expanding
epidemic, and yet no defined roles have been described (7).
Recombinant SARS-CoV bearing variant spikes from zoo-
notic and early-, middle-, and late-phase human isolates were
viable, formed plaques, and replicated efficiently in Vero E6
cells, although replication was delayed for the zoonotic strains.
Zoonotic strains were incapable of producing extensive CPE
but evolved a CPE phenotype with serial passage. Since RNA
viruses are known for their high mutational rate, serial passage
of SARS-CoV has been shown to select for tissue culture-
associated mutations in the spike glycoprotein as well as other
structural and nonstructural ORFs (43). In addition, the oc-
currence of a CPE phenotype for the SARS-CoV bearing zoo-
notic spikes after several passages indicates that one or more
mutations likely evolved with passage in Vero E6 cells. Sur-
prisingly, independent passage of the zoonotic isolates selected
amino acid changes located at flanking amino acids 577 and
578. The S glycoprotein mutations mapped in a region of
unknown function flanked by the fusion peptide and receptor
binding domains roughly 200 and 77 codons away, respec-
tively. Similar adaptations have been shown previously for an-
other icSARS-CoV bearing the GD03 S glycoprotein at posi-
FIG. 8. Light photomicrographs of alveolar parenchyma from 12-month-old mice that were mock inoculated (A) or inoculated with recom-
binant SARS-CoV spike glycoprotein variant icUrbani (B), icGZ02 (C), icHC/SZ/61/03 (D), icCUHK-W1 (E), or icA031G (F) and sacrificed 4
days after inoculation. No microscopic lesions are evident in panel A, B, E, or F. Diffuse acute alveolitis with alveolar septal congestion (dotted
arrows with open arrowhead) and numerous hyaline membranes in alveolar airspaces (arrows with closed arrowheads) are present in panels C and
D. AL, alveoli; AD, alveolar ducts; BV, blood vessels. Tissues were stained with hematoxylin and eosin. Scaling bars, 50 m.
VOL. 81, 2007 LETHAL SARS-CoV INFECTION IN AGED MICE 7419
 o
n
 June 3, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
tions 7 and 613 (10). Adaptive mutations in the S glycoprotein
have been implicated in coronavirus adaptation and extended
host studies (9), although involvement of unknown mutations
in ORF1a/ORF1b cannot be excluded. The lack of mutations
in the S genes of strains icUrbani, icCUHK-W1, and icGZ02 as
well as in the rest of the 3 end of the SARS-CoV genome
indicates that the reverse genetic system can be readily used to
introduce mutations in the S gene without subsequent rever-
sion or extensive adaptation, making this an attractive tool for
studying the effects of heterogeneity in the S gene in a stable
genetic background of the Urbani isolate.
The similarity between the growth curve kinetics of the rac-
coon dog spike variant A031G and those of the human isolates
suggests that the delay occurred at entry. This is in agreement
with previous observations that binding efficiency of SARS-
CoV to its receptor ACE-2 decreases dramatically in the pres-
ence of one or two amino acid changes within the RBD (32).
The two amino acids (479N and 487T) are located in the
binding interface of the S-ACE-2 complex (29), and while most
of the early- to late-phase human isolates contain an aspara-
gine and threonine, respectively, animal isolates contain an
arginine (isolate HC/SZ/61/03; A013G) or lysine at position
479 and a serine at position 487, potentially interfering with
interactions between human ACE-2 and the RBD of SARS-
CoV S glycoprotein. Although mutations within the RBD may
affect the efficiency of binding to ACE-2, all spike variant
SARS-CoV isolates depended on the presence of ACE-2 for
binding and entry in Vero E6 cells. In a more relevant model,
HAE cell cultures mimicking the architecture of the human
ciliated airway cells have been shown to express abundant
levels of human ACE-2 on their apical surfaces, which perhaps
even serve as an initial site of virus replication (52). Surpris-
ingly, zoonotic S glycoprotein variants were inefficient at in-
fecting HAE cell cultures despite the expression of the SARS-
CoV receptor ACE-2 on target cells in the cultures (52). This
is in agreement with the observation that zoonotic SARS-CoV
isolates produce attenuated pathogenesis in humans (23) and
suggests either a block postentry, as these viruses were shown
to depend on ACE-2 and cathepsin L for binding and entry in
a fashion similar to that seen with the human S variants, or
insufficient availability of ACE-2 to initiate productive infec-
tions. Our data provide empirical support for the hypothesis
that most zoonotic strains harbored in palm civets and raccoon
dogs would likely require additional rounds of evolution and
change to promote efficient replication and human-to-human
transmission (23).
Studies focusing on virus-receptor interactions and blocking
thereof have mainly used a limited subset of pseudotyped vi-
ruses expressing the different SARS-CoV S glycoproteins (14,
38, 63). Although pseudotyped viruses allow for the easy in-
troduction of mutations into the SARS-CoV S gene and
present with limited biosafety issues, this system remains arti-
ficial and structural differences in the S glycoprotein cannot be
excluded. Potential problems with these systems are demon-
strated by contradicting observations of antibody-mediated en-
hancement (16, 63, 64). By using the reverse genetics systems
developed for Urbani SARS-CoV to introduce the variant S
genes from the zoonotic and human isolates, we ensured the
proper structural expression of the S glycoprotein on the viri-
ons and demonstrated that all mutants tested used ACE-2 and
cathepsin L efficiently to mediate entry into susceptible Vero
E6 cells.
Currently a variety of animal models exist for studying
SARS-CoV, including mice, ferrets, hamsters, cats, and non-
human primates (27, 34, 35, 47, 55). In young BALB/c mice,
peak virus replication occurred on day 1 or 2, with virus clear-
ance in a week in the absence of any clinical disease or pathol-
ogy (55). For senescent mice, virus titers are increased and
mild pathological lesions are noted in the lungs of infected
animals at 4 days postinfection (45). Some animals may expe-
rience limited weight loss, but symptoms are mild overall. As
none of these models recapitulate the complex pathogenic
phenotype noted during the SARS-CoV epidemic in humans,
animal models that are more robust are needed to evaluate the
efficacy of SARS-CoV vaccines and therapeutics, especially in
the more vulnerable elderly populations. The recent adapta-
tion of the Urbani isolate to mice by serial passage of the virus
in the respiratory tract of young BALB/c mice resulted in a
virus that is lethal in young BALB/c mice after intranasal
inoculation and that showed extensive pathological changes
(44). Histopathologic changes after inoculation with this
mouse-adapted virus included damage to bronchiolar and al-
veolar epithelial cells but not the alveolar edema and damage
to hyaline membranes that were reported for many SARS-
CoV-infected patients (12, 18, 44). During passage the virus
did, however, acquire six coding mutations, including one in
the S glycoprotein, all of which were necessary for the lethal
phenotype (44). Two other groups described lethal SARS-CoV
Urbani models of mouse infection involving development of
transgenic mice expressing human ACE-2 (36, 60). Although
high titers of SARS-CoV could be found in lungs of the trans-
genic mice, infection rapidly spread to the central nervous
system, resulting in encephalitis and death. These models do
not recapitulate the novel age-related phenotype of SARS
pathogenesis or the principle histological changes of diffuse
alveolar damage, hyaline membrane formation, respiratory
failure, and death.
In this study, we developed two new lethal SARS-CoV chal-
lenge models employing mice with SARS-CoV isolates bearing
S glycoproteins from an early human isolate (GZ02) and a
palm civet isolate (HC/SZ/61/03), making use of mutations in
the S glycoprotein that naturally occurred during the epidemic.
Three amino acid changes in the S glycoprotein of SARS-CoV
were associated with a lethal phenotype in aged mice, including
one each in the receptor binding domain, the putative FP
region, and the HR-2 region. Mutations in the HR and FP
domains of mouse hepatitis virus have previously been shown
to affect host ranges in vitro and pathogenesis in vivo (9, 59).
Mice infected with viruses bearing these three mutations
showed clinical signs, lost significant amounts of weight, and
died by day 4. In addition, virus replication was primarily
restricted to the lungs, with low levels of replication found in
peripheral organs like the liver, spleen, and kidney but not the
brain. Surprisingly, peak viral titers in the lung were not higher
in mice infected with the lethal isolates; in fact, mice infected
with the lethal icHC/Z/61/03 isolate had titers in the lungs that
were 1 to 2 logs lower. This discrepancy between viral titers
and increased pathogenesis may be explained by observations
that SARS is characterized by immunopathological damage
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caused by a “cytokine storm” (20) and not by direct patholog-
ical damage due to viral replication.
The pathology observed in mice infected with these two
lethal S glycoprotein variants was very similar to the pathology
observed in acute human cases of SARS-CoV. Mice died of
ARDS characterized by DAD and hyaline membrane forma-
tion within 3 to 4 days after intranasal infection (8, 12). Both
the development of ARDS and the increased pathogenic phe-
notype in older individuals are in complete agreement with
data from human SARS-CoV cases (5, 33). Two phases have
been identified during SARS-CoV infection in humans (41).
ARDS develops within the first 10 days with DAD, edema, and
hyaline membrane formation (39, 40). After the acute phase,
organizing DAD with increased fibrosis is observed (40).
ARDS has been shown to be the major cause of death in cases
of human infection by SARS-CoV and avian influenza A
(H5N1) (39) and likely the 1918 influenza virus (25). Robust
model systems designed to study the complex pathogenesis of
virus-induced ARDS are rare (25, 62) and are limited to select
influenza viruses and the two SARS-CoV models described in
the current report; these models provide a rare opportunity to
study the complex virus-host interactions that contribute to this
severe acute pathogenic phenotype, especially in association
with aging.
To our knowledge these are the only lethal SARS-CoV
infection models using mice and the SARS-CoV spike glyco-
protein isolates that occurred naturally during the outbreak
and that recapitulate the age-related pathogenic phenotype.
Further studies into the pathogenesis of these lethal S glyco-
protein variants of SARS-CoV are under way.
This panel of lethal viruses will be invaluable for testing
vaccine candidates and monoclonal antibodies for their ability
to protect and/or neutralize heterologous SARS-CoV isolates.
To date, several vaccine candidates have been developed and
tested in different animal models. However, all of these stud-
ies, except one, have focused on vaccination and challenge with
the homologous virus strain most often isolated from the late
phase of the SARS-CoV epidemic (3, 10, 49, 54). By the use of
a recombinant virus bearing a GD03 S glycoprotein, vaccine
efficacy was reduced in aged animals, suggesting that more-
rigorous testing of vaccines in models reflecting the vulnera-
bility of elderly populations is central to improved public
health (10). In addition, SARS-CoV isolates bearing zoonotic
S glycoproteins were only neutralized at high concentrations of
monoclonal antibodies which readily neutralize the human iso-
lates. This is in agreement with other studies showing limited
cross-neutralization when using pseudotyped viruses (16, 63).
The absence of human cases of SARS-CoV in the last two
years suggests that a new outbreak of SARS-CoV would likely
result from zoonotic transmission (2). Therefore, vaccines
against SARS-CoV should protect against a wide variety of
strains, particularly from the zoonotic and early epidemic
phases, to prevent further transmission and adaptation.
Our data show that the S glycoprotein of SARS-CoV can be
replaced by variant S glycoproteins, thereby allowing construc-
tion of a panel of SARS-CoV isolates bearing S glycoproteins
from different phases of the epidemic of 2002 and 2003. We
developed two new mouse models for heterologous SARS-
CoV infection that reflect human cases of SARS by both age
dependence and pathological changes. As immune senescence
is a critical mediator of disproportionate disease burdens in the
elderly (37), we believe that this panel will be a powerful tool
for studying the complex age-related relationship to ARDS
and the effect of spike glycoprotein heterogeneity on virus-
receptor interactions, host-interactions, tropism, and patho-
genesis as well as an essential model for successful vaccine
development for aged populations.
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